

Please type a plus sign (+) inside this box

PTO/SB/08A (10-88)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			<i>Complete if Known</i>		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	09/779,086	
			Filing Date	herewith	
			First Named Inventor	Chinery	
			Group Art Unit	1639	
			Examiner Name		
Sheet	1	of	3	Attorney Docket Number	ATH 108 CON1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/779,086
				Filing Date	2/7/01
				First Named Inventor	Chinery
				Group Art Unit	1631
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	ATH 108 CON1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
M	BA	COFFEY, et al., <i>Cancer Res.</i> 47, 4590 (1987)			T
	BB	CROOK, et al. <i>Oncogene</i> 6, 873 (1991)			
	BC	SCHEFFNER, et al. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88, 5523 (1991)			
	BD	RIPOLL, et al., Vitamin E Enhances the Chemotherapeutic Effects of Adriamycin, <i>Biological Abstracts</i> , 82, 82084938			
	BE	YAUNAGA et al., Vitamin E and Cancer Therapy-Experimental Study in Mice, Database National Cancer Institute, 1982.			
	BF	SZCZEPANSKA et al., Inhibition of Leukocyte Migration by Cancer Chemotherapeutic Agents and its Prevention by Free Radical Scavengers and Thiols, <i>Biological Abstracts</i> Vol. 85, 85106445			
	BG	PRASAD et al., Vitamin E Increases the Growth Inhibitory and Differentiating Effects of Tumor Therapeutic Agents on Neuro Blastoma and Glioma Cells in Culture, <i>Biological Abstracts</i> , vol. 70, 70052454			
	BH	DRAGO, et al., Chemptherapy and Vitamin E in Treatment of NB Rat Prostrate Tumors, <i>Biological Abstracts</i> Vol. 88, 88006807			
	BI	CLOOS JACQUELINE JAN, Influence of the antioxidant N-acetylcysteine and its metabolites on Damage induced by Bleomycin in PM2 Bacteriophage, <i>Biological Abstracts</i> , Vol. 96, 98730849.			
	BJ	RIORDAN et al., Case study: High Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney, <i>J. Orthomolecular Med.</i> , 5:1, 1990, 5-7.			
	BK	CAMPBELL et al., Reticulum Cell Sarcoma: Two Complete "Spontaneous" Regressions, in Response to High-Dose Ascorbic Acid Therapy, <i>Oncology</i> , 48: 6 (1991), 495-497.			
	BL	BONGERS, Antioxidant-Related Parameters in Patients Treated for Cancer Chemoprevention with N-acetylcysteine, <i>Biological Abstracts</i> , vol. 95, 98363146.			
	BM	OFFERMAN, et al. AntioxidantSensitive Regulation of Inflammatory_Response Genes in Kaposi's Sarcoma Cells, <i>J. of AIDS and Hum. Retro.</i> , (1996) 13:1-11.			
M	BN	TYAGI S C, Reduction-Oxidation state Regulation of Extracellular Matrix Metalloproteinases and Tissue Inhibitors in Cardiac Normal and Transformed Fibroblast Cells, <i>Biological Abstracts</i> , vol. 96, 98730849.			

Examiner Signature	<i>B. Celsa</i>	Date Considered	2/11/04
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (10-96)

Approved for use through 10/31/98. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	09/779,086
			Filing Date	2/7/01
			First Named Inventor	Chinery
			Group Art Unit	1639
			Examiner Name	
(use as many sheets as necessary)			Attorney Docket Number	ATH 108 CON1
Sheet	3	of	3	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner P.C. COLGAT Date 3/10/04

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.